Last reviewed · How we verify
ddAC-mini CTC
ddAC-mini CTC is a targeted therapy that uses a combination of drugs to target cancer cells.
ddAC-mini CTC is a targeted therapy that uses a combination of drugs to target cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | ddAC-mini CTC |
|---|---|
| Sponsor | The Netherlands Cancer Institute |
| Drug class | Targeted therapy |
| Target | Multiple molecular targets |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ddAC-mini CTC is a combination of drugs that work together to target cancer cells by inhibiting certain proteins that are involved in cell growth and division. This approach allows for a more targeted and effective treatment of cancer.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ddAC-mini CTC CI brief — competitive landscape report
- ddAC-mini CTC updates RSS · CI watch RSS
- The Netherlands Cancer Institute portfolio CI